Atomo Diagnostics

About

Atomo Diagnostics designs and manufactures integrated, user-focused rapid diagnostic devices (AtomoRapid) for capillary blood point-of-care and self-testing of infectious diseases, offering finished products, OEM solutions, and digital reader integration.

Mission

Atomo Diagnostics designs and manufactures user-centric rapid diagnostic test (RDT) devices that use capillary blood and integrate multiple test components into a single all-in-one device. The company focuses on simple, safe, low-cost RDT solutions aimed at reducing user error and misdiagnosis in field and home settings. Its AtomoRapid™ HIV 1&2 professional-use test won ‘Best in Show’ at the 2014 Medical Design Excellence Awards, reflecting the firm’s emphasis on usability and design. Atomo’s products target screening for infectious and chronic conditions, with particular attention to low- and middle-income country needs. The company plans to develop a next-generation HIV self-test for global health markets and to engage public and private partners, researchers, health workers and end users to support commercial launches in high-burden countries. Financially, Atomo has received a US$2.6 million grant from the Bill & Melinda Gates Foundation and recent equity funding from the Global Health Investment Fund to support development and commercialization efforts. Atomo Diagnostics develops a platform of innovative, user-friendly rapid diagnostic devices and services for point-of-care and consumer testing. The company emphasizes quick, accurate and affordable diagnostics intended to deliver clinical and economic value to healthcare consumers and providers. Its devices are positioned for infectious-disease detection, including HIV, with potential application in Africa and other global markets. Management says the platform improves convenience, simplicity and user experience for testing. Atomo recently received further capital support as it seeks to expand its presence in the global health market. GHIF involvement on the board is expected to support the company’s commercial expansion. Atomo Diagnostics is a point-of-care diagnostics company that develops the AtomoRapid™ platform—an integrated, single‑device rapid diagnostic test intended to replace multi‑component lateral flow kits. The platform is designed to improve usability, reduce user error, and enable professional and consumer self-testing for infectious diseases. Atomo supplies its platform as both finished products and OEM solutions for diagnostic partners, and its AtomoRapid HIV professional test launched in early 2014 and has won industry awards. The company is commercializing self-test solutions for HIV and other infectious diseases and is finalizing a Hepatitis C test, working on combination tests as well as digital readers and e-health capabilities. Financially, Atomo received a $6 million loan from the Global Health Investment Fund to scale production and expand commercial activities. Atomo is based in Sydney, Australia.

Quick Facts